{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:08:41Z","timestamp":1791943721964,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U20A20366"],"award-info":[{"award-number":["U20A20366"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472198"],"award-info":[{"award-number":["82472198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mcponline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular & Cellular Proteomics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.mcpro.2025.101488","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T02:37:51Z","timestamp":1765593471000},"page":"101488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Plasma Proteome-Driven Liquid Biopsy for Individualized Monitoring and Risk Stratification of Immune-Related Adverse Events in Checkpoint Immunotherapy"],"prefix":"10.1016","volume":"25","author":[{"given":"Dongxue","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9987-9024","authenticated-orcid":false,"given":"Meng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcpro.2025.101488_bib1","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2025.101488_bib2","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.mcpro.2025.101488_bib3","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.mcpro.2025.101488_bib4","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.mcpro.2025.101488_bib5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s43588-024-00748-8","article-title":"Leveraging pharmacovigilance data to predict population-scale toxicity profiles of checkpoint inhibitor immunotherapy","volume":"5","author":"Yan","year":"2025","journal-title":"Nat. Comput. Sci."},{"key":"10.1016\/j.mcpro.2025.101488_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.mcpro.2025.101488_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.mcpro.2025.101488_bib8","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.mcpro.2025.101488_bib9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bph.70195","article-title":"Decoding fatal toxic effects in checkpoint inhibitor therapy using real-world pharmacovigilance data and machine learning","volume":"183","author":"Yan","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mcpro.2025.101488_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2017162","article-title":"Association between immune-related adverse event timing and treatment outcomes","volume":"11","author":"Hsiehchen","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.mcpro.2025.101488_bib11","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.mcpro.2025.101488_bib12","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.6004\/jnccn.2020.7567","article-title":"Multiorgan immune-related adverse events during treatment with atezolizumab","volume":"18","author":"Kichenadasse","year":"2020","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.mcpro.2025.101488_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang","year":"2021","journal-title":"Cancer Res. Treat"},{"key":"10.1016\/j.mcpro.2025.101488_bib14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mcpro.2025.101488_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00262-019-02303-1","article-title":"Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma","volume":"68","author":"Abu-Sbeih","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.mcpro.2025.101488_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001935","article-title":"Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA","volume":"9","author":"Kalinich","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.mcpro.2025.101488_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002896","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data","volume":"9","author":"Reynolds","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.mcpro.2025.101488_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mcpro.2025.101488_bib19","doi-asserted-by":"crossref","first-page":"8392","DOI":"10.1038\/s41467-023-44255-2","article-title":"Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma","volume":"14","author":"Xing","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2025.101488_bib20","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41591-022-01850-y","article-title":"Noninvasive proteomic biomarkers for alcohol-related liver disease","volume":"28","author":"Niu","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcpro.2025.101488_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41571-021-00597-8","article-title":"Harnessing big data to characterize immune-related adverse events","volume":"19","author":"Jing","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.mcpro.2025.101488_bib22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/clinchem\/hvaa081","article-title":"Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis","volume":"66","author":"Gerber","year":"2020","journal-title":"Clin. Chem."},{"key":"10.1016\/j.mcpro.2025.101488_bib23","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.mcpro.2025.101488_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.mcpro.2025.101488_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.mcpro.2025.101488_bib26","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving Anti-PD-1-Based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2025.101488_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.medj.2022.12.007","article-title":"Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors","volume":"4","author":"Nunez","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.mcpro.2025.101488_bib28","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1038\/s41467-023-39486-2","article-title":"The proteomic landscape of soft tissue sarcomas","volume":"14","author":"Burns","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2025.101488_bib29","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.mcpro.2025.101488_bib30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13046-020-01749-x","article-title":"The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors","volume":"39","author":"Jia","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2025.101488_bib31","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1038\/s41591-022-02094-6","article-title":"Germline variants associated with toxicity to immune checkpoint blockade","volume":"28","author":"Groha","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.mcpro.2025.101488_bib32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nrd.2016.233","article-title":"Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity","volume":"16","author":"Lesterhuis","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mcpro.2025.101488_bib33","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s00432-019-03002-1","article-title":"C-reactive protein as an early marker of immune-related adverse events","volume":"145","author":"Abolhassani","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.mcpro.2025.101488_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1479-5876-11-75","article-title":"Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events","volume":"11","author":"Shahabi","year":"2013","journal-title":"J. Transl Med."},{"key":"10.1016\/j.mcpro.2025.101488_bib35","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2025.101488_bib36","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review","volume":"6","author":"Yoest","year":"2017","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.mcpro.2025.101488_bib37","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.mcpro.2025.101488_bib38","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.mcpro.2025.101488_bib39","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00262-021-02855-1","article-title":"Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors","volume":"70","author":"Tyan","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.mcpro.2025.101488_bib40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13046-018-0872-6","article-title":"Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours","volume":"37","author":"Nwosu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.mcpro.2025.101488_bib41","doi-asserted-by":"crossref","first-page":"10484","DOI":"10.1039\/D1FO01849C","article-title":"Quantitative proteomics of plasma and liver reveals the mechanism of turmeric in preventing hyperlipidemia in mice","volume":"12","author":"Wang","year":"2021","journal-title":"Food Funct."},{"key":"10.1016\/j.mcpro.2025.101488_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/science.adg7942","article-title":"Persistent complement dysregulation with signs of thromboinflammation in active long covid","volume":"383","author":"Cervia-Hasler","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.mcpro.2025.101488_bib43","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.mcpro.2025.101488_bib44","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.4049\/jimmunol.0901575","article-title":"IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation","volume":"183","author":"Kurowska-Stolarska","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.mcpro.2025.101488_bib45","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrd2660","article-title":"The IL-33\/ST2 pathway: therapeutic target and novel biomarker","volume":"7","author":"Kakkar","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mcpro.2025.101488_bib46","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.mcpro.2025.101488_bib47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-021-27631-8","article-title":"Systematic analysis of drug-associated myocarditis reported in the world health Organization pharmacovigilance database","volume":"13","author":"Nguyen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcpro.2025.101488_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170503","article-title":"Pulmonary toxicity of immune checkpoint immunotherapy","volume":"134","author":"Ghanbar","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.mcpro.2025.101488_bib49","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/pcmr.12958","article-title":"Germline variants in exonic regions have limited impact on immune checkpoint blockade clinical outcomes in advanced melanoma","volume":"34","author":"Montaudi\u00e9","year":"2021","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.mcpro.2025.101488_bib51","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.mcpro.2025.101488_bib52","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.chest.2021.02.032","article-title":"Immune checkpoint inhibitor-related pneumonitis in lung cancer: Real-world incidence, risk factors, and management practices across six health care centers in North Carolina","volume":"160","author":"Atchley","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.mcpro.2025.101488_bib53","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007324","article-title":"Management of immune-related cutaneous adverse events with dupilumab","volume":"11","author":"Kuo","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.mcpro.2025.101488_bib54","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.gpb.2021.08.001","article-title":"The genome sequence archive family: toward explosive data growth and diverse data types","volume":"19","author":"Chen","year":"2021","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"10.1016\/j.mcpro.2025.101488_bib55","doi-asserted-by":"crossref","first-page":"D18","DOI":"10.1093\/nar\/gkad1078","article-title":"China National Center for Bioinformation in 2024","volume":"52","year":"2024","journal-title":"Nucleic Acids Res."}],"container-title":["Molecular & Cellular Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947625005870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1535947625005870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:54:15Z","timestamp":1770792855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535947625005870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1535947625005870"],"URL":"https:\/\/doi.org\/10.1016\/j.mcpro.2025.101488","relation":{},"ISSN":["1535-9476"],"issn-type":[{"value":"1535-9476","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma Proteome-Driven Liquid Biopsy for Individualized Monitoring and Risk Stratification of Immune-Related Adverse Events in Checkpoint Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular & Cellular Proteomics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcpro.2025.101488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"101488"}}